WAM
KYNB

Wolverine Asset Management’s Kyntra Bio KYNB Stock Holding History

Wolverine Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10
Closed -$46K – 1246
2016
Q1 		$46K Buy
+10
New +$4.98K ﹤0.01% 874

Other funds holding KYNB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wolverine Asset Management's KYNB Position: Q3 2020 in Review

Wolverine Asset Management sold out of Kyntra Bio (KYNB) in Q3 2020, closing a stake of 15 shares — an estimated $14K sold.

Wolverine Asset Management first reported a position in KYNB in Q2 2020 and held it in 1 quarter. The position peaked at $14K in Q2 2020. 208 funds tracked by Wall St. Rank hold KYNB as of Q3 2020.

  • Wolverine Asset Management reported no remaining Kyntra Bio position as of Q3 2020 after selling out during the quarter.
  • Wolverine Asset Management sold 15 Kyntra Bio shares in Q3 2020, an estimated $14K.
  • Wolverine Asset Management first reported a position in Kyntra Bio in Q2 2020 and held it in 1 quarter.
  • Wolverine Asset Management's Kyntra Bio position peaked at $14K in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2020.

Based on Wolverine Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.